10-K: AngioDynamics Reports FY2026 Results, Focus on Med Tech Growth

AngioDynamics, Inc. announced its fiscal year 2026 results, highlighting a 9.5% increase in net sales driven by its Med Tech segment, while navigating a net loss and implementing strategic restructuring initiatives.

Summary

• AngioDynamics reported a 9.5% increase in net sales for fiscal year 2026, reaching $320.2 million.
• The Med Tech segment saw significant growth of 18.4%, driven by Auryon, thrombus management, and NanoKnife products.
• The Med Device segment experienced a more modest 2.6% growth, primarily due to increases in Core and Venous product lines.
• The company reported a net loss of $36.7 million, an increase from the previous year's net loss of $34.0 million.
• A restructuring plan to optimize manufacturing is ongoing, expected to yield $15.0 million in annual cost savings starting in fiscal year 2027.
• The company has a $25.0 million secured revolving credit facility, with no outstanding balance as of May 31, 2026.
• James C. Clemmer, President and CEO, announced his intention to retire, with a search for a successor underway.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as mixed; while revenue growth is positive, the increased net loss and ongoing restructuring indicate challenges that temper overall sentiment.

Positives

• Net sales increased by 9.5% to $320.2 million in fiscal year 2026.
• Med Tech segment net sales grew by 18.4%, indicating strong performance in key technology areas.
• Gross margin improved to 54.6% from 53.9% in the prior year.
• Cash flow from operations turned positive, increasing by $13.2 million to $3.1 million.
• The company secured a $25.0 million revolving credit facility, providing financial flexibility.
• Several clinical trials and studies are progressing, including enrollment in AMBITION BTK and RECOVER-AV trials, and publication of NanoKnife PRESERVE study data.
• Received FDA IDE approval for APEX-Return study and PAVE clinical study.
• Finalized a local coverage determination with Palmetto for NanoKnife IRE for qualifying Medicare patients.

Negatives

• Net loss increased to $36.7 million from $34.0 million in the prior year.
• Loss per share increased to $0.88 from $0.83.
• Restructuring activities are ongoing and have incurred significant costs.
• The company faces intense competition in the medical device industry.
• Reliance on single or limited source suppliers poses a risk to operations.
• International sales represent a relatively small portion of total revenue (14%).
• The company has a history of impairments and may face future charges.
• The company is subject to extensive regulatory oversight and potential enforcement actions.

Risks

• Intense competition and industry consolidation may impact market share and revenue.
• Rapid technological change requires continuous innovation and product development.
• Dependence on third-party manufacturers introduces risks related to control and quality.
• Changes in healthcare regulations and reimbursement policies could adversely affect demand and pricing.
• Product liability claims and potential recalls could result in significant costs and reputational damage.
• Failure to protect intellectual property rights could harm market position.
• Cybersecurity threats could disrupt operations and compromise sensitive data.
• The CEO's upcoming retirement introduces leadership transition risks.

Future Outlook

The company is focused on its Med Tech segment, aiming for growth through innovative R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. Investments in Auryon, Mechanical Thrombectomy, and NanoKnife are expected to drive access to larger and faster-growing markets. The ongoing restructuring is projected to generate $15.0 million in annual cost savings starting in fiscal year 2027.

Management Comments

• "Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance."
• "We expect our businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products and increasing our presence internationally."
• "The Company is focused on its Med Tech segment which is committed to expanding treatment options and improving patient outcomes and quality of life by focusing on cardiovascular disease and cancer."
• "As previously disclosed, Mr. Clemmer has announced his intention to retire on the earlier of November 30, 2026 and appointment of a successor CEO."

Industry Context

StockSavvy.ai notes that AngioDynamics' focus on its Med Tech segment, particularly in areas like peripheral arterial disease (Auryon) and thrombectomy (AngioVac, AlphaVac), aligns with broader industry trends towards minimally invasive treatments and advanced medical technologies. The company's strategic restructuring and investment in R&D are common approaches for medical device companies seeking to maintain competitiveness in a rapidly evolving market.

Management Changes

Legal Proceedings

• Ongoing defense against approximately 412 product liability claims involving the Company's port products, consolidated in the U.S. District Court for the Southern District of California.
• Settlement agreement with Becton, Dickinson and Company (BD) resolving patent infringement litigation, involving a one-time payment and future minimum annual payments.
• Patent infringement lawsuit filed against Endovascular Engineering, Inc. (E2) alleging infringement of the Company's proprietary self-expanding funnel technology.

Stakeholder Impact

• Shareholders may be impacted by the increased net loss and the ongoing CEO transition, potentially affecting stock price.
• Employees may be affected by restructuring initiatives and the CEO transition.
• Customers will continue to receive products and services, with a focus on Med Tech segment growth.
• Suppliers may face continued demand, but the company's restructuring could alter supply chain dynamics.

Next Steps

• Complete manufacturing footprint restructuring by Q1 FY2027.
• Continue R&D and clinical trial progression for key products like NanoKnife, Auryon, and thrombectomy systems.
• Execute CEO transition plan.
• Monitor and manage costs amidst inflationary pressures and supply chain challenges.

Key Dates

Recommendation

The company shows revenue growth in its key Med Tech segment, which is positive. However, the increased net loss, ongoing restructuring costs, and the upcoming CEO transition introduce significant uncertainty. A 'hold' recommendation is appropriate pending clearer signs of profitability improvement and successful leadership transition.

Keywords

AngioDynamics, Form 10-K, Medical Technology, Med Tech, Med Device, Auryon, NanoKnife, Financial Results